Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Buys Peloton On Eve Of IPO, Expands Kidney Cancer Portfolio

May 22 2019

• By Mandy Jackson

Human kidney cross section on scientific background showing adrenal gland as well. 3d illustration — Acquiring Peloton will expand Merck's kidney cancer portfolio • Source: Shutterstock

Related Content

Cancer drug start-up Peloton raises $18M

Jul 29 2011

IPO Update: Pace Of US Offerings Slows As 13 Biopharmas Go Public In 2019

May 01 2019

Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors

Feb 02 2019

Finance Watch: Scripps Research Models A New Way To Fund Translation

Feb 26 2019

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Pfizer Inc.

Merck KGaA

Cubist Pharmaceuticals, Inc.

Idenix Pharmaceuticals, Inc.

Exelixis, Inc.

Novartis AG

The University of Texas System

Additional Topics

Deals M & A Business Strategies Companies Commercial Cancer BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window